Maria Tountopoulou

Charité - Universitätsmedizin Berlin

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Angela M. Kaindl

Charité - Universitätsmedizin Berlin

Bernhard Weschke

Charité - Universitätsmedizin Berlin

Viola Roggenkamp

Charité - Universitätsmedizin Berlin

Cooperative Institutions

Charité - Universitätsmedizin Berlin

Humboldt-Universität zu Berlin

Freie Universität Berlin

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

German Center for Pediatric and Adolescent Rheumatology

University Hospital Bonn

DRK Kliniken Berlin

Institute of Cell Biology and Neurobiology

Ludwig-Maximilians-Universität München

Goethe University Frankfurt

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Anti-convulsant Agents: Ethosuximide and Methsuximide

Springer eBooks (2022)

Maria Tountopoulou Angela M. Kaindl

Ethosuximide

Convulsants

Juvenile myoclonic epilepsy

Valproic Acid

10.1007/978-3-030-62059-2_275

Cite

Citations (0)

Lacosamide Lowers Valproate and Levetiracetam Levels

Neuropediatrics (2017)

Bernhard Weschke Angela M. Kaindl Maria Tountopoulou

Abstract Lacosamide (LCM) due to no known drug interaction and the absence of metabolic enzyme induction is a good candidate for an add-on medication, especially in combination with lamotrigine, levetiracetam (LEV), oxcarbazepine, topiramate, and valproic acid (VPA). Here we report for the first time, to our knowledge, that LCM can lower VPA and LEV serum levels. At present, there are no known explicable mechanisms of action of LCM, which lowers VPA and LEV. Here observed drug interaction of LCM is of clinical significance, which might be useful for other colleagues in the field.

Lacosamide

Levetiracetam

Oxcarbazepine

Valproic Acid

10.1055/s-0037-1600112

Cite

Citations (7)

Lacosamide Lowers Valproate and Levetiracetam Levels

Neuropediatrics (2017)

Maria Tountopoulou Viola Roggenkamp Bernhard Weschke Angela M. Kaindl

Background: Lacosamide (LCM) has no known drug interaction or metabolic enzyme induction and is, thus, a good add-on medication. Here we report for the first time that LCM can lower valproate (VPA) and levetiracetam (LEV) serum levels.

Lacosamide

Levetiracetam

Piracetam

Antiepileptic drug

Valproic Acid

10.1055/s-0037-1602972

Cite

Citations (0)

Anti-convulsant Agents: Ethosuximide and Methsuximide

Springer eBooks (2020)

Maria Tountopoulou Angela M. Kaindl

Ethosuximide

Convulsants

10.1007/978-3-319-56015-1_275-1

Cite

Citations (0)